• Home
  • A Vaccine to End a Pandemic?

A Vaccine to End a Pandemic?

17 Nov 2020 5:16 PM | Anonymous

By: Annalisa Torres, PharmD Candidate 2021; St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis

Mentor: Paul Juang, PharmD, BCPS, BCCP, FASHP, FCCM; Professor, Department of Pharmacy Practice, St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis

SARS-CoV-2 and COVID-19

As 2019 drew to a close, the world saw the emergence of a novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease known as Coronavirus disease 2019 (COVID-19). This highly pathogenic coronavirus was originally identified in Wuhan, China and would eventually spread to the rest of the global population resulting in a modern worldwide pandemic. The increased morbidity and mortality associated with COVID-19 resulted in the need for both the rapid manufacturing and global distribution of a safe and effective vaccine that is unparalleled.1 Due to its highly infectious nature that has resulted in numerous mortalities along with the global economic impact, understanding how SARS-CoV-2 enters the cell is an important factor in vaccine development.2

Like its predecessor, severe acute respiratory syndrome coronavirus (SARS-CoV), which resulted in the 2003 SARS outbreak, SARS-CoV-2, is a betacornoavirus that gains entry into the host cell via a spike protein (S2) that is present as a trimer on viral cell surfaces. A receptor binding domain for angiotensin-converting enzyme 2 (ACE2) is located on S protein resulting in the entry of both SARS-CoV and SARS-CoV-2 into the host cell. While the mechanism for entry is the same, slight variations in the receptor binding domain of SARS-CoV-2 result in a higher binding affinity for ACE2 compared to SARS-CoV.2 This mechanism has been the key area of interest related to COVID-19 vaccine development.3

Vaccine Development

Generally, it takes between 15 and 20 years before a safe and effective vaccine is available for distribution to the public.5,6 But given the need for more rapid vaccine development a public – private partnership known as Operation Warp Speed (OWS) was formed in May 2020. OWS is a partnership between the Department of Health and Human Services (HHS), the Department of Defense (DOD), and the private sector in order to accelerate not only vaccine development but also manufacturing and distribution, in the hopes of being able to provide at least 100 million doses by mid-2021.7

mRNA Vaccines: Moderna and Pfizer/BioNTech

A novel approach to vaccine development, messenger RNA (mRNA) based vaccines work on the notion that mRNA coded for pathogen antigen, in this case SARS-CoV-2, can not only be delivered to human cells but can then be used to produce antigen within the cell. mRNA vaccine technology synthesizes the viral protein by utilizing the human protein translational process. This method of vaccine delivery allows for a robust immune response without the introduction of live or inactivated portions of SARS-CoV-2. Due to its susceptibility to be rapidly degraded by ribonucleases, these vaccines need to be encapsulated with a lipid nanoparticle.5,6 Both Moderna in conjunction with NIAID (National Institute of Allergy and Infectious Disease) and Pfizer in conjunction with BioNTech have developed an mRNA based vaccine that encodes for spike protein found on the surface of SARS-CoV-2. 5,8,9

Adenovirus Vector Vaccines: AstraZeneca and Janssen

The vaccines currently being developed by AstraZeneca in conjunction with University of Oxford and Janssen Pharmaceuticals are known as replication-incompetent vectors. These vaccines have been engineered to express the spike protein found on SARS-CoV-2 while also disabling in vivo replication. Both vaccines are based on adenovirus vectors that deliver the spike protein to human cells. Upon entry into host cells, these vectors will allow for the expression of the spike protein, resulting in an immune response. While these vaccine types have been shown to elicit a good B and T cell response, they are somewhat affected by pre-existing vector immunity. In order to overcome this issue, vector types are either rare in humans, animal derived, or induce low immunity.5,6

Inactive Spike Protein Vaccines: Novavax and Sanofi/GlaxoSmithKline

The vaccine candidates being put forth by Novavax and Sanofi/GlaxoSmithKline utilize inactivated viral vectors to display the SARS-CoV-2 spike protein.5 The benefit of these vaccine types is that they are not only safe in immunocompromised individuals, and they have been extensively utilized in prior viral protein-based vaccines.6 NVX-CoV2373, the vaccine candidate from Novavax, includes the transmembrane domain of the wild-type SARS-CoV-2 spike (S) protein. As mentioned above, S mediates the attachment of SARS-CoV-2 to human cells.10

Table 1, comparing the current available data for the six leading COVID-19 vaccine candidates, is shown below.


References:

  1. Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&D. Science. 2020;368(6494):948-950.
  2. Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117(21):11727-11734.
  3. Seyedpour S, Khodaei B, Loghman AH, et al. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies [published online ahead of print, 2020 Sep 9]. J Cell Physiol. 2020;10.1002/jcp.30032.
  4. Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945-946.
  5. O'Callaghan KP, Blatz AM, Offit PA. Developing a SARS-CoV-2 Vaccine at Warp Speed. JAMA. 2020;324(5):437-438.
  6. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516-527.
  7. Slaoui M, Hepburn M. Developing Safe and Effective Covid Vaccines - Operation Warp Speed's Strategy and Approach. N Engl J Med. 2020;383(18):1701-1703.
  8. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report [published online ahead of print, 2020 Jul 14]. N Engl J Med. 2020;NEJMoa2022483.
  9. Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates [published online ahead of print, 2020 Oct 14]. N Engl J Med. 2020;NEJMoa2027906.
  10. Keech C, Albert G, Cho I, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine [published online ahead of print, 2020 Sep 2]. N Engl J Med. 2020;NEJMoa2026920.
  11. Pfizer. Pfizer investor day features significant number of pipeline advances for COVID-19 programs and across numerous therapeutic areas. Pfizer Web site. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-investor-day-features-significant-number-pipeline. September 15, 2020. Accessed November 8, 2020.
  12. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial [published correction appears in Lancet. 2020 Aug 15;396(10249):466]. Lancet. 2020;396(10249):467-478.
  13. Simões E, Burger L. AstraZeneca COVID-19 vaccine trial Brazil volunteer dies, trial to continue. Reuters Web site. https://www.reuters.com/article/health-coronavirus-brazil-vaccine-int-idUSKBN2762OV. October 21,2020. Accessed November 7, 2020.
  14. Robbins R, Feurestein A, Branswell H. AstraZeneca Covid-19 vaccine study put on hold due to suspected adverse reaction in participant in the U.K. STAT News Web site. https://www.statnews.com/2020/09/08/astrazeneca-covid-19-vaccine-study-put-on-hold-due-to-suspected-adverse-reaction-in-participant-in-the-u-k/. September 8, 2020. Accessed November 7, 2020.
  15. Sadoff J, Le Gars M, Shukarev G, et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. [published online ahead of print September 25,2020]. medRxiv. doi 10.1101/2020.09.23.20199604.
  16. Taylor NP. J&J starts COVID-19 vaccine phase 3, eyes early 2021 approval. FIERECE Biotech Web site. https://www.fiercebiotech.com/biotech/j-j-starts-covid-19-vaccine-phase-3-eyes-early-2021-approval. September 23, 2020. Accessed November 8, 2020.
  17. Branswell H. Novavax, maker of a Covid-19 vaccine, is backed by Operation Warp Speed. STAT News Website. https://www.statnews.com/2020/07/07/novavax-maker-of-a-covid-19-vaccine-is-backed-by-operation-warp-speed/. July 7, 2020. Accessed November 8, 2020.
  18. GlaxoSmithKline. Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate. GlaxoSmithKline Web site. https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-initiate-phase-12-clinical-trial-of-covid-19-adjuvanted-recombinant-protein-based-vaccine-candidate/#. September 3, 2020. Accessed November 8, 2020.
  19. Moderna. Moderna announces longer shelf life for its COVID-19 vaccine candidate at refrigerated temperatures. Moderna Web site. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-longer-shelf-life-its-covid-19-vaccine. November 16, 2020. Accessed November 17, 2020.

  20. Word Health Organization. Draft landscape of COVID-19 candidate vaccines. Word Health Organization Web site. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. November 12, 2020. Accessed November 17, 2020.


Upcoming events


Copyright 2020, Missouri Society of Health-System Pharmacists
501(c)6 non-profit organization. 2650 S. Hanley Rd., Suite 100, St. Louis, MO 63144 
p: (314) 416-2246, f: (314) 845-1891, www.moshp.org
Powered by Wild Apricot Membership Software